Results 211 to 220 of about 92,614 (315)

Emerging Risk: Intranasal Tin Exacerbates Allergic Rhinitis in Humans and Mice

open access: yes
Allergy, EarlyView.
Delgama A. S. M. Nishadhi   +9 more
wiley   +1 more source

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

open access: yesAllergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller   +16 more
wiley   +1 more source

Monocyte Chemotactic Factors in the Airways of Patients With Mild Asthma Before and After an Allergen Challenge

open access: yes
Allergy, EarlyView.
Nami Shrestha Palikhe   +7 more
wiley   +1 more source

Dendrimeric Antigens for Passive Mast Cell Activation in the Evaluation of Amoxicillin Allergy

open access: yesAllergy, EarlyView.
DeAns with defined nanoscale structure reveal that conjugate size and determinant density govern IgE‐mediated effector‐cell activation in AX allergy. All DeAn generations bind to sIgE in inhibition immunoassay, but only larger DeAns trigger FcεRI‐dependent responses in mouse MC, huRBL‐2H3, and LUVA cells.
Amene Tesfaye Ayane   +12 more
wiley   +1 more source

Elevated CO2 and Temperature Alter Grass Pollen's Ability to Modify Transcriptome and Function of the Nasal Epithelium

open access: yesAllergy, EarlyView.
We exposed human nasal epithelial tissues to pollen from grasses grown under different climate treatments (temperature and CO2). Pollen weakened epithelial tight junctions and altered cytokine‐related gene expression, with similar protein‐level effects.
Tarleena Tossavainen   +5 more
wiley   +1 more source

Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema

open access: yesAllergy, EarlyView.
This study performed an unbiased molecular profiling of CHE patients across diverse etiologies to identify shared pathogenic drivers and evaluate the impact of IL‐4Rα blockade via dupilumab over 16 weeks. CHE shows a mixed immune signature involving type 1, 2, and 3 pathways with features of atopic dermatitis and psoriasis.
Perrine Gery   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy